Skip to content
thispeptide

Hers

Hers’ current weight-care menu centers on brand GLP-1 medicines, with a separate care membership and ongoing messaging. Its clinical network, state restrictions and earlier FDA marketing warning all matter to the decision.

Review by Molly Ward, goal-guide writer · Updated October 2026

The short version

Hers publishes a clear separation between care and medication and offers ongoing access to clinicians. Check the specific treatment, pharmacy and continuing cost before joining; the current brand-drug menu does not resolve the FDA’s separate historical concern about compounded semaglutide advertising.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

FDA warning letter on record: Letter 716825 · September 2025

Hers is a consumer telehealth platform offering weight-management care and other health services. Its current menu names Wegovy pill and pen options, Zepbound formats and other brand treatments. Medication requires an appropriate prescription and an active weight-loss membership. Different formulations and brands are not interchangeable simply because they appear on the same menu.

What Hers prescribes, by goal

Weight

  • SemaglutideFDA-approved
    • Injection (brand)Price not published
    • Oral (brand)Price not published
  • TirzepatideFDA-approved
    • Injection (brand)Price not published
  • OrforglipronFDA-approved
    • Oral (brand)Price not published

The current menu includes brand semaglutide and tirzepatide options. The clinician chooses a suitable treatment after reviewing the patient’s circumstances; joining does not guarantee a prescription or a particular drug. Oral and injected products have different instructions, evidence and prices, so confirm the actual prescription rather than choosing from a generic GLP-1 headline.

Who prescribes

A licensed clinician

Hims & Hers Health, Inc. supplies the platform rather than practicing medicine. The October 2026 terms identify the You Health medical groups in several states as the clinical network employing or contracting with providers. A state-licensed clinician assesses the individual patient. The terms name multiple pharmacy relationships, including Curexa, Red Rock, Strive and Apostrophe, while some manufacturer self-pay prescriptions can go to independent Gifthealth. Those lists do not establish which pharmacy will fill a particular prescription.

An intake gathers health history and treatment goals for clinician review. A video or audio visit may be required depending on the state and clinical situation. The weight-loss terms include routine monthly clinical check-ins, visits for medication or dose adjustments as needed, and unlimited provider messaging. Unlimited access to send messages is not a guaranteed immediate response. Ongoing care is tied to maintaining the membership.

Are labs required?

Confirm with the clinician

The telehealth consent discusses laboratory testing and names laboratory relationships. The weight-care material reviewed does not establish the same required panel for every GLP-1 patient or a universal testing charge. Ask which tests are needed in your case and who pays for them.

Ready to start with Hers?

Prices and plans are set on the seller's own site.

What it claims, and what it cites

The current weight-loss page uses brand-drug trial findings and selected patient stories. Trial results describe the studied medicine and population, rather than a measured guarantee for everyone using Hers. On September 9, 2025, the FDA issued warning letter CMS 716825 to Hims & Hers Health, Inc. dba Hers. It concerned August 2025 advertising of compounded semaglutide that the agency said misleadingly implied sameness to FDA-approved products. The current brand menu is a different offering. No FDA closeout was confirmed for that letter. A changed product page alone does not establish agency resolution.

Other products and treatment claims

Non-peptide health treatments and anti-nausea medication
These may form part of wider care but are outside the peptide products this site compares.

How it bills

The FAQ lists a $39 first membership month and a $149 monthly renewal, with medication billed separately. Drug price and billing interval depend on the prescribed product and plan. The lowest advertised medicine amount should therefore not be read as the ongoing total for care and every dose. Membership and medication can be separate renewing subscriptions. Canceling medication alone leaves the membership running. The terms describe cancellation through the app, online subscriptions area or support, with two-day deadlines for the circumstances specified there. An external pharmacy’s billing and cancellation rules can also apply.

For and against

  • For: Named medical-group structure in the terms
  • For: Monthly check-ins and provider messaging described
  • For: Care fee and medication charge distinguished
  • For: Several brand formulations offered
  • Against: Medication costs extra
  • Against: GLP-1 care not available in every state
  • Against: Messaging response times vary
  • Against: Historical FDA advertising warning has no confirmed closeout here

The evidence behind what it sells

Right for

Someone seeking app-based weight care with brand medicine choices and comfortable managing the care membership and pharmacy plan separately.

Look elsewhere if

Someone expecting one low advertised drug price to include all care, or someone requiring immediate clinician responses.

Other sellers for weight

Hers

Frequently asked questions

Does Hers’ membership include GLP-1 medication?
No. The FAQ separates the care membership from medication, which has its own product- and plan-dependent charge.
Are video visits always required?
The FAQ says the requirement depends on the state. A clinician may use the intake or arrange an audio or video visit.
What did the FDA warning concern?
The September 2025 letter concerned claims about compounded semaglutide in August 2025 advertising. It should not be presented as a finding about every current branded prescription. No agency closeout was confirmed.

Sources

See what Hers prescribes today

Hers sets its own prices, plans and the states it serves. Check them before you start.

Written by Molly Ward from Hers’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.